US8513202B2 - Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate - Google Patents
Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate Download PDFInfo
- Publication number
- US8513202B2 US8513202B2 US13/103,557 US201113103557A US8513202B2 US 8513202 B2 US8513202 B2 US 8513202B2 US 201113103557 A US201113103557 A US 201113103557A US 8513202 B2 US8513202 B2 US 8513202B2
- Authority
- US
- United States
- Prior art keywords
- thienylmethyl
- methyl
- hemihydrate
- glucopyranosyl
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IUNOTFMZOIQMFN-TXMBMYLBSA-N C.CC.CC1=C(CC2=CC=C(C3=CC=C(F)C=C3)S2)C=C(Br)C=C1.CC1=C(CC2=CC=C(C3=CC=C(F)C=C3)S2)C=C([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1.CC[C@H]1OC(=O)[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@@H]1O[Si](C)(C)C.CC[SiH](CC)CC.COC1(C2=CC(CC3=CC=C(C4=CC=C(F)C=C4)S3)=C(C)C=C2)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.[Li]CCCC Chemical compound C.CC.CC1=C(CC2=CC=C(C3=CC=C(F)C=C3)S2)C=C(Br)C=C1.CC1=C(CC2=CC=C(C3=CC=C(F)C=C3)S2)C=C([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1.CC[C@H]1OC(=O)[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@@H]1O[Si](C)(C)C.CC[SiH](CC)CC.COC1(C2=CC(CC3=CC=C(C4=CC=C(F)C=C4)S3)=C(C)C=C2)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.[Li]CCCC IUNOTFMZOIQMFN-TXMBMYLBSA-N 0.000 description 1
- AGVTWARIBWSYFY-HFBCXCLPSA-N CC1=CC=C(C2=CC=C(CC3=C(C)C=CC([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)=C3)S2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(CC3=C(C)C=CC([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)=C3)S2)C=C1 AGVTWARIBWSYFY-HFBCXCLPSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- This invention relates to a crystalline form of 1-( ⁇ -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate useful as an inhibitor of sodium-dependent glucose transporter, to methods for its preparation and isolation, to pharmaceutical compositions which include the compound and a pharmaceutically acceptable carrier, and to pharmaceutical methods of treatment.
- WO 2005/012326 pamphlet discloses a class of compounds that are inhibitors of sodium-dependent glucose transporter (SGLT) and thus of therapeutic use for treatment of diabetes, obesity, diabetic complications, and the like.
- SGLT sodium-dependent glucose transporter
- the product should be in a form that is readily filterable and easily dried. Additionally, it is economically desirable that the product be stable for extended periods of time without the need for specialized storage conditions.
- the present invention provides a crystalline form of hemihydrate of the compound of formula (I) as a novel material, in particular in pharmaceutically acceptable form.
- FIG. 1 is a diagrammatic representation of FIG. 1 :
- FIG. 2
- the inventors of the present invention have found that the compounds of formula (I) can be crystallized from a water-containing solvent and the crystalline form of hemihydrate of the compounds (I) have good handling qualities and characteristics.
- the present invention is directed to:
- a process for the preparation of a crystalline of hemihydrate of 1-( ⁇ -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene which comprises forming a solution of 1-( ⁇ -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and crystallizing said hemihydrate from the solution by precipitation or recrystallization.
- a pharmaceutical composition comprising an effective amount of a crystalline of hemihydrate of 1-( ⁇ -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and a pharmaceutically acceptable carrier. 7.
- a method for treatment or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension which comprises administering a therapeutically effective amount of a crystalline of hemihydrate of 1-( ⁇ -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene.
- the present invention includes a certain solid state crystalline form.
- the diffraction peak intensities in the experimental patterns can vary, as is known in the art, primarily due to preferred orientation (non-random orientation of the crystals) in the prepared sample.
- the scope of the present invention must be considered in light of the variability of characterization that is appreciated by those skilled in the art.
- the crystalline form of the present invention (I) is characterized by its X-ray powder diffraction pattern.
- the X-ray diffraction pattern of the crystalline of hemihydrate of the compound (I) was measured on an X-ray diffractometer (RINT-TTR III, Rigaku, Tokyo, Japan) with measured using CuK ⁇ radiation.
- Methodology of X-ray powder diffraction is as follows:
- Scan range: from 3 to 40.0 degree.
- the infra-red spectrum of the crystalline form of the present invention in mineral oil comprises the following main peaks: 1626, 1600, 1549, and 1507 cm ⁇ 1 .
- the crystalline form of the present invention has been observed to exist in a hemihydrate form.
- the theoretical water content of the crystalline of the present invention is 1.98%.
- the thermogravimetric analysis for the crystalline of the present invention shows a mass loss of 1.705%.
- thermogravimetric analysis is as follows: about 8 mg of compound (I) hemihydrate is weighed and transferred in an aluminum cell holder for TG-50 (Shimadzu, Japan), and then, the thermogravimetric (TG) thermal curve of crystalline compound (I) hemihydrate is determined at a heat rate of 5° C./minute. Typical measuring range is from ambient to 150° C.
- the present invention also provides a process for producing the crystalline form of hemihydrate of the compound (I) which comprises forming a solution of compound (I) and precipitating the crystalline form from solution.
- the crystalline of hemihydrate of the compound (I) may be obtained from a mixture of the compound of formula (I), a good solvent and water, optionally containing a poor solvent.
- impurities may act as crystallization inhibitors, and impurities need to be removed using a conventional manner, such as silica gel column chromatography.
- a conventional manner such as silica gel column chromatography.
- the crystalline of hemihydrate of the compound of formula (I) can even be obtained from relatively impure compound (I).
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the crystalline of hemihydrate of the compound (I) and a pharmaceutically acceptable carrier.
- the crystalline compound of the present invention possesses activity as inhibitors of sodium-dependent glucose transporters, and show excellent blood glucose lowering effect.
- the crystalline form of the present invention are expected to be useful in the treatment, prevention or delaying the progression or onset of diabetes mellitus (type 1 and type 2 diabetes mellitus, etc.), diabetic complications (such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy), postprandial hyperglycemia, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, atherosclerosis, or hypertension.
- diabetes mellitus type 1 and type 2 diabetes mellitus, etc.
- diabetic complications such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy
- postprandial hyperglycemia delayed wound healing
- insulin resistance hyperglycemia
- hyperinsulinemia elevated blood levels of fatty acids
- elevated blood levels of glycerol hyperlipidemia
- obesity hypertriglyceridemia
- crystalline form of the present invention or a pharmaceutically acceptable salt thereof may be administered either orally or parenterally, and can be used in the form of a suitable pharmaceutical preparation.
- suitable pharmaceutical preparations for oral administration include, for example, solid preparations such as tablets, granules, capsules, and powders, or solution preparations, suspension preparations, emulsion preparations, and the like.
- Suitable pharmaceutical preparations for parenteral administration include, for example, suppositories; injection preparations or intravenous drip preparations, using distilled water for injection, physiological saline solution or aqueous glucose solution; and inhalant preparations.
- compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, from about 0.01 mg/kg to about 100 mg/kg body weight (preferably from about 0.01 mg/kg to about 50 mg/kg; and, more preferably, from about 0.01 mg/kg to about 30 mg/kg) of the active ingredient, and may be given at a dosage of from about 0.01 mg/kg/day to about 100 mg/kg/day (preferably from about 0.01 mg/kg/day to about 50 mg/kg/day and more preferably from about 0.01 mg/kg/day to about 30 mg/kg/day).
- dosage unit e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, from about 0.01 mg/kg to about 100 mg/kg body weight (preferably from about 0.01 mg/kg to about 50 mg/kg; and, more preferably, from about 0.01 mg/kg to about 30 mg/kg) of the active ingredient, and may be given at a dosage of from
- the method of treating a disorder described in the present invention may also be carried out using a pharmaceutical composition comprising the crystalline form as defined herein and a pharmaceutical acceptable carrier.
- the dosage form will contain from about 0.01 mg/kg to about 100 mg/kg (preferably from about 0.01 mg/kg to about 50 mg/kg; and, more preferably, from about 0.01 mg/kg to about 30 mg/kg) of the active ingredient, and may be constituted into any form suitable for the mode of administration selected.
- the dosages may be varied depending upon administration routes, the requirement of the subjects, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.
- the crystalline form of the present invention may be used, if necessary, in combination with one or more of other anti-diabetic agents, antihyperglycemic agents and/or agents for treatment of other diseases.
- the present compounds and these other agents may be administered in the same dosage form, or in a separate oral dosage form or by injection.
- the dosage of those agents may vary according to, for example, ages, body weight, conditions of patients, administration routes, and dosage forms.
- compositions may be orally administered to mammalian species including human beings, apes, and dogs, in the dosage form of, for example, tablet, capsule, granule or powder, or parenterally administered in the form of injection preparation, or intranasally, or in the form of transdermal patch.
- the crystalline form of hemihydrate of the compound of formula (I) can be prepared from a mixture of the compound (I), a good solvent and water, optionally containing a poor solvent.
- Examples of good solvents which have been found suitable include ketones (e.g., acetone, 2-butanone), esters (e.g., ethyl acetate, methyl acetate), alcohols (e.g., methanol, ethanol, i-propanol), and a mixture of these solvents.
- Examples of poor solvents include alkanes (e.g., hexane, heptane), aromatic hydrocarbons (e.g., benzene, toluene), ethers (e.g., diethyl ether, dimethyl ether, diisopropyl ether) and a mixture of these solvents.
- One preferred preparation of the crystalline form of hemihydrate of the compound of formula (I) typically involves dissolving in a good solvent (e.g., ketones or esters) crude or amorphous compound of formula (I) prepared in accordance with the procedures described in WO 2005/012326 pamphlet, and adding water and a poor solvent (e.g., alkanes or ethers) to the resulting solution, followed by filtration.
- a good solvent e.g., ketones or esters
- a poor solvent e.g., alkanes or ethers
- water is preferably used in amount of 1 to 10 molar equivalents to the compound of formula (I)
- the good solvent is preferably used in amount of 10 to 100 times of volume of water
- the poor solvent is preferably used in amount of 0.1 to 10 times of volume of the good solvent.
- the precise conditions under which the crystalline of hemihydrate of the compound (I) is formed may be empirically determined.
- crystallization can preferably be carried out at a lowered, ambient or elevated temperature.
- the crystalline form of hemihydrate of the compound of formula (I) is significantly easier to isolate than amorphous form of the compound and can be filtered from the crystallization medium after cooling, and washed and dried. Also, the crystalline form of the present invention is more stable than the amorphous form of the compound of formula (I).
Abstract
Description
3. A crystalline of hemihydrate of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, having substantially the same X-ray powder diffraction pattern as set out in
4. A crystalline of hemihydrate of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, having substantially the same IR spectrum, as set out in
5. A process for the preparation of a crystalline of hemihydrate of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, which comprises forming a solution of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and crystallizing said hemihydrate from the solution by precipitation or recrystallization.
6. A pharmaceutical composition comprising an effective amount of a crystalline of hemihydrate of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and a pharmaceutically acceptable carrier.
7. A method for treatment or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension, which comprises administering a therapeutically effective amount of a crystalline of hemihydrate of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/103,557 US8513202B2 (en) | 2006-12-04 | 2011-05-09 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86842606P | 2006-12-04 | 2006-12-04 | |
JP2006-327019 | 2006-12-04 | ||
JP2006327019 | 2006-12-04 | ||
US11/987,670 US7943582B2 (en) | 2006-12-04 | 2007-12-03 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
US13/103,557 US8513202B2 (en) | 2006-12-04 | 2011-05-09 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/987,670 Continuation US7943582B2 (en) | 2006-12-04 | 2007-12-03 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110212905A1 US20110212905A1 (en) | 2011-09-01 |
US8513202B2 true US8513202B2 (en) | 2013-08-20 |
Family
ID=38973167
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/987,670 Active 2029-02-26 US7943582B2 (en) | 2006-12-04 | 2007-12-03 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
US13/103,557 Active US8513202B2 (en) | 2006-12-04 | 2011-05-09 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/987,670 Active 2029-02-26 US7943582B2 (en) | 2006-12-04 | 2007-12-03 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Country Status (34)
Country | Link |
---|---|
US (2) | US7943582B2 (en) |
EP (1) | EP2102224B2 (en) |
JP (1) | JP5159788B2 (en) |
KR (1) | KR101146095B1 (en) |
CN (3) | CN101573368B (en) |
AR (3) | AR064099A1 (en) |
AU (1) | AU2007329895C1 (en) |
BR (1) | BRPI0718882B8 (en) |
CA (1) | CA2671357C (en) |
CL (1) | CL2007003487A1 (en) |
CO (1) | CO6210719A2 (en) |
CR (1) | CR10861A (en) |
DK (1) | DK2102224T4 (en) |
EA (1) | EA017103B1 (en) |
EC (1) | ECSP099489A (en) |
ES (1) | ES2456640T5 (en) |
GT (1) | GT200900151A (en) |
IL (1) | IL199032A (en) |
ME (1) | ME01829B (en) |
MX (1) | MX2009005857A (en) |
MY (1) | MY153702A (en) |
NO (1) | NO344354B1 (en) |
NZ (1) | NZ577545A (en) |
PA (1) | PA8759401A1 (en) |
PE (3) | PE20130591A1 (en) |
PL (1) | PL2102224T5 (en) |
PT (1) | PT2102224E (en) |
RS (1) | RS53274B2 (en) |
SI (1) | SI2102224T2 (en) |
SV (1) | SV2009003285A (en) |
TW (1) | TWI403325B (en) |
UY (1) | UY30730A1 (en) |
WO (1) | WO2008069327A1 (en) |
ZA (1) | ZA200903941B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014195966A2 (en) | 2013-05-30 | 2014-12-11 | Cadila Healthcare Limited | Amorphous form of canagliflozin and process for preparing thereof |
US9573959B2 (en) | 2013-03-14 | 2017-02-21 | Msd International Gmbh | Methods for preparing SGLT2 inhibitors |
US10544135B2 (en) | 2011-04-13 | 2020-01-28 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US10617668B2 (en) | 2010-05-11 | 2020-04-14 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
WO2021214023A1 (en) | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2022067724A1 (en) | 2020-09-30 | 2022-04-07 | 北京睿创康泰医药研究院有限公司 | Sglt-2 inhibitor sarcosine co-crystal, preparation method therefor and use thereof |
US11576894B2 (en) | 2009-07-08 | 2023-02-14 | Janssen Pharmaceutica Nv | Combination therapy for the treatment of diabetes |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY30730A1 (en) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE |
JP5596545B2 (en) * | 2007-09-10 | 2014-09-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Method for producing a compound useful as an inhibitor of SGLT |
JP5749168B2 (en) | 2008-08-22 | 2015-07-15 | セラコス・インコーポレイテッドTheracos, Inc. | Method for producing SGLT2 inhibitor |
US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
ES2797503T3 (en) | 2009-02-13 | 2020-12-02 | Boehringer Ingelheim Int | Pharmaceutical composition comprising an SGLT2 inhibitor, a DPP-IV inhibitor and optionally an additional antidiabetic agent and their uses |
EP2451797B1 (en) * | 2009-07-10 | 2013-04-03 | Janssen Pharmaceutica, N.V. | CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE |
US8869918B2 (en) | 2009-10-07 | 2014-10-28 | Longyear Tm, Inc. | Core drilling tools with external fluid pathways |
BR112012008939B1 (en) * | 2009-10-14 | 2021-06-22 | Janssen Pharmaceutica Nv | PROCESS FOR PREPARING COMPOUNDS USEFUL AS SGLT2 INHIBITORS |
WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
CN102115468B (en) * | 2009-12-31 | 2014-06-11 | 上海特化医药科技有限公司 | Synthesis method of 2, 5-disubstituted thiophene compound |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
JP2013523681A (en) | 2010-03-30 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical composition comprising SGLT2 inhibitor and PPAR-gamma agonist and use thereof |
KR101869110B1 (en) | 2010-05-11 | 2018-06-19 | 미쓰비시 타나베 파마 코퍼레이션 | Canagliflozin containing tablets |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
EP2590631B1 (en) | 2010-07-06 | 2016-10-26 | Janssen Pharmaceutica NV | Formulation for co-therapy treatment of diabetes |
WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
TWI542596B (en) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | L-proline and citric acid co-crystals of (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol |
EP2714052B1 (en) | 2011-06-03 | 2018-09-19 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9018249B2 (en) | 2011-09-13 | 2015-04-28 | Panacea Biotec Limited | SGLT inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2773359A4 (en) * | 2011-10-31 | 2015-10-21 | Scinopharm Taiwan Ltd | Crystalline and non-crystalline forms of sglt2 inhibitors |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
CN103965267A (en) * | 2013-01-24 | 2014-08-06 | 江苏豪森医药集团连云港宏创医药有限公司 | 1-(beta-D-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and L-phenylalanine eutectic compound and preparation method thereof |
JP2016512817A (en) | 2013-03-15 | 2016-05-09 | ヤンセン ファーマシューティカ エヌ.ベー. | Combination of canagliflozin and probenecid in the treatment of hyperuricemia |
HUE064190T2 (en) | 2013-04-04 | 2024-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
BR112015028096B1 (en) | 2013-05-08 | 2022-04-26 | Lek Pharmaceuticals D.D. | Crystalline form of a hydrate, process for preparing the crystalline form, pharmaceutical composition, use of crystalline form and pharmaceutical combination |
WO2015051484A1 (en) | 2013-10-12 | 2015-04-16 | Theracos, Inc. | Preparation of hydroxy-benzylbenzene derivatives |
CN103641822B (en) * | 2013-10-21 | 2016-06-08 | 江苏奥赛康药业股份有限公司 | A kind of Ka Gelie purifies compound and pharmaceutical composition thereof |
EP3068779A4 (en) * | 2013-11-11 | 2017-06-28 | Crystal Pharmatech Co. Ltd. | Crystalline forms b, c, and d of canagliflozin |
CN103588762A (en) * | 2013-11-27 | 2014-02-19 | 苏州晶云药物科技有限公司 | Novel crystal form of canagliflozin and its preparation method |
PL3082829T3 (en) | 2013-12-17 | 2021-09-06 | Boehringer Ingelheim Vetmedica Gmbh | Sglt2 inhibitors for the treatment of metabolic disorders in feline animals |
US10603300B2 (en) * | 2014-01-23 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
CN113082021A (en) * | 2014-01-31 | 2021-07-09 | 詹森药业有限公司 | Method for treating and preventing renal and fatty liver diseases |
WO2015139386A1 (en) * | 2014-03-19 | 2015-09-24 | 杭州普晒医药科技有限公司 | Canagliflozin monohydrate and crystal form thereof, preparation method and use thereof |
CN103980262B (en) * | 2014-04-01 | 2016-06-22 | 天津大学 | The B crystal form of canagliflozin and crystallization preparation method thereof |
CN103980261B (en) * | 2014-04-01 | 2016-06-29 | 天津大学 | The A crystal formation of canagliflozin and crystallization preparation method thereof |
CA2943704C (en) | 2014-04-01 | 2023-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
CN103896930B (en) * | 2014-04-02 | 2016-08-17 | 安徽联创生物医药股份有限公司 | The preparation method of canagliflozin semihydrate medicinal crystal-form |
EP2933255A1 (en) | 2014-04-17 | 2015-10-21 | LEK Pharmaceuticals d.d. | Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene |
CN103936726B (en) * | 2014-04-18 | 2016-06-15 | 王军 | Crystal, preparation method and its usage |
CN103936800A (en) * | 2014-05-08 | 2014-07-23 | 安徽联创药物化学有限公司 | Preparation method of 1-(1-methoxy pyran glucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl] benzene |
EP2947077A1 (en) | 2014-05-19 | 2015-11-25 | LEK Pharmaceuticals d.d. | Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides |
CN105330706B (en) * | 2014-06-05 | 2019-04-16 | 江苏豪森药业集团有限公司 | The preparation method of canagliflozin intermediate |
CN105319294B (en) * | 2014-06-20 | 2021-03-30 | 重庆医药工业研究院有限责任公司 | Method for separating and determining canagliflozin and related substances thereof |
CN104761546A (en) * | 2014-06-21 | 2015-07-08 | 山东富创医药科技有限公司 | Novel (1S)-1,5-dehydro-1-[3-[[5-(4-(4-fluorophenyl)-2-thiophene] methyl]-4-methyl phenyl)-D-glucitol crystal form and preparation method thereof |
WO2016016774A1 (en) * | 2014-07-31 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Crystalline forms of canagliflozin |
EP2990029A1 (en) | 2014-08-29 | 2016-03-02 | Sandoz Ag | Pharmaceutical compositions comprising Canagliflozin |
US20170247359A1 (en) | 2014-09-05 | 2017-08-31 | Mylan Laboratories Ltd. | Process for the preparation of canagliflozin |
CZ2014634A3 (en) | 2014-09-16 | 2016-03-23 | Zentiva, K.S. | Canagliflozin and cyclodextrin complexes |
CN104402946B (en) * | 2014-11-17 | 2018-01-02 | 连云港恒运药业有限公司 | Canagliflozin intermediate and its unbodied preparation method |
CN105753910A (en) * | 2014-12-16 | 2016-07-13 | 康普药业股份有限公司 | Preparation method of canagliflozin intermediate |
CN104530023A (en) * | 2014-12-25 | 2015-04-22 | 重庆医药工业研究院有限责任公司 | Crystal form I of Canagliflozin and preparation method thereof |
CN104945392A (en) * | 2015-01-27 | 2015-09-30 | 江苏嘉逸医药有限公司 | Crystal-type canagliflozin-hydrate as well as preparation method and application of crystal-type canagliflozin hydrate |
CN104530024B (en) | 2015-02-04 | 2017-08-08 | 上海迪赛诺药业有限公司 | Crystal formation of 1 (β D glycopyranosyls) 4 methyl 3 [5 (4 fluorophenyl) 2 thienyl methyls] benzene and preparation method thereof |
JP2018087140A (en) * | 2015-02-27 | 2018-06-07 | 田辺三菱製薬株式会社 | NOVEL CRYSTAL OF 1-(β-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE |
WO2016135747A2 (en) * | 2015-02-27 | 2016-09-01 | Msn Laboratories Private Limited | Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof |
WO2016142950A1 (en) * | 2015-03-11 | 2016-09-15 | Harman Finochem Limited | A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form |
JP6916740B2 (en) | 2015-05-22 | 2021-08-11 | ヤンセン ファーマシューティカ エヌ.ベー. | Anhydrous crystalline form of (1S) -1,5-anhydro-1- [3-[[5- (4-fluorophenyl) -2-thienyl] methyl] -4-methylphenyl] -D-glucitol |
CN106279134A (en) * | 2015-06-23 | 2017-01-04 | 中美华世通生物医药科技(武汉)有限公司 | Canagliflozin monocrystalline and its production and use |
CZ2015435A3 (en) | 2015-06-25 | 2017-01-04 | Zentiva, K.S. | Amorphous canagliflozin solid forms |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
ES2896101T3 (en) | 2015-09-15 | 2022-02-23 | Laurus Labs Ltd | SGLT2 inhibitor co-crystals, process for their preparation and pharmaceutical compositions thereof |
WO2017064679A1 (en) * | 2015-10-15 | 2017-04-20 | Lupin Limited | Process for the preparation of amorphous canagliflozin |
WO2017071813A1 (en) * | 2015-10-30 | 2017-05-04 | Zaklady Farmaceutyczne Polpharma Sa | Process for the preparation of a pharmaceutical agent |
CZ2015824A3 (en) | 2015-11-20 | 2017-05-31 | Zentiva, K.S. | A crystalline form of Canagliflozin and the method of its preparation |
EA036793B1 (en) * | 2015-12-21 | 2020-12-22 | Янссен Фармацевтика Нв | Crystallization process for obtaining canagliflozin hemihydrate crystals |
CN105541818A (en) * | 2016-03-04 | 2016-05-04 | 浙江华海药业股份有限公司 | Novel crystal form of canagliflozin hydrate and preparation method of novel crystal form |
CN107540706A (en) * | 2016-06-28 | 2018-01-05 | 山东诚创医药技术开发有限公司 | The preparation method of ipragliflozin intermediate |
WO2018020506A1 (en) | 2016-07-25 | 2018-02-01 | Natco Pharma Ltd | Process for the preparation of amorphous form of canagliflozin |
KR20190070956A (en) | 2016-10-19 | 2019-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | Compositions comprising SSAO / VAP-1 inhibitor and SGLT2 inhibitor and uses thereof |
CN108017626A (en) * | 2016-11-04 | 2018-05-11 | 上海奥博生物医药技术有限公司 | A kind of canagliflozin semihydrate novel crystal forms |
CN106588898A (en) | 2017-02-20 | 2017-04-26 | 浙江华海药业股份有限公司 | Preparation method for amorphous form of canagliflozin |
EA202090028A1 (en) | 2017-06-12 | 2020-04-03 | Янссен Фармацевтика Нв | METHODS FOR REDUCING OR PREVENTING CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE II DIABETES |
CN109553649B (en) * | 2017-09-26 | 2020-12-04 | 北大方正集团有限公司 | Preparation method of canagliflozin intermediate |
AU2019254371A1 (en) | 2018-04-17 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
TW202103709A (en) | 2019-03-26 | 2021-02-01 | 比利時商健生藥品公司 | Methods for treating subjects with chronic kidney disease |
KR20220109431A (en) | 2019-11-28 | 2022-08-04 | 베링거잉겔하임베트메디카게엠베하 | Use of SGLT-2 Inhibitors in Non-Human Mammalian Dry Milk |
KR20220143732A (en) | 2020-02-17 | 2022-10-25 | 베링거잉겔하임베트메디카게엠베하 | Use of SGLT-2 inhibitors to prevent and/or treat heart disease in felines |
CN113943329A (en) * | 2020-07-16 | 2022-01-18 | 尚科生物医药(上海)有限公司 | Preparation method of diastereoisomer of canagliflozin intermediate |
AU2022318037A1 (en) | 2021-07-28 | 2024-02-22 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
WO2023006718A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
US20230381101A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
Citations (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160861A (en) | 1977-10-03 | 1979-07-10 | Merck & Co., Inc. | Method for the separation of antibiotic macrolides |
US4584369A (en) | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
JPS63233975A (en) | 1986-10-07 | 1988-09-29 | Wako Pure Chem Ind Ltd | Tcnq complex |
EP0355750A1 (en) | 1988-08-19 | 1990-02-28 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
JPH04253974A (en) | 1991-02-05 | 1992-09-09 | Ishihara Sangyo Kaisha Ltd | Sulfonylurea compound, its production and herbicide containing the same |
US5149838A (en) | 1991-09-20 | 1992-09-22 | Merck & Co., Inc. | Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents |
WO1993021178A1 (en) | 1992-04-14 | 1993-10-28 | Pfizer Limited | Indole derivatives as 5-ht1-like agonists |
EP0579204A2 (en) | 1992-07-15 | 1994-01-19 | Kao Corporation | Dye composition for a keratinous fiber |
US5424406A (en) | 1992-11-12 | 1995-06-13 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
WO1997025033A1 (en) | 1995-10-31 | 1997-07-17 | Eli Lilly And Company | Antithrombotic diamines |
JPH09263549A (en) | 1996-01-25 | 1997-10-07 | Fujisawa Pharmaceut Co Ltd | Production of benzene derivative |
US5731292A (en) | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
US5767094A (en) | 1995-11-07 | 1998-06-16 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and processes for preparing the same |
US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US5830873A (en) | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
JPH10324632A (en) | 1997-03-25 | 1998-12-08 | Takeda Chem Ind Ltd | Pharmaceutical composition |
JP2000034230A (en) | 1998-07-17 | 2000-02-02 | Pola Chem Ind Inc | Sulfur-containing antifungal agent |
JP2000034239A (en) | 1998-07-16 | 2000-02-02 | Asahi Glass Co Ltd | Production of trifluoromethylated aromatic compound |
US6048842A (en) | 1996-12-26 | 2000-04-11 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivatives and process for preparing the same |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
WO2000074681A1 (en) | 1999-06-03 | 2000-12-14 | Pfizer Limited | Metalloprotease inhibitors |
WO2001027128A1 (en) | 1999-10-12 | 2001-04-19 | Bristol-Myers Squibb Company | C-aryl glucoside sglt2 inhibitors |
GB2359554A (en) | 2000-02-02 | 2001-08-29 | Kotobuki Pharmaceutical Compan | C-Glycosides and preparation thereof as antidiabetic agents |
WO2001064669A1 (en) | 2000-03-03 | 2001-09-07 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
WO2001068660A1 (en) | 2000-03-17 | 2001-09-20 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
US6297363B1 (en) | 1993-02-12 | 2001-10-02 | Nomura Co., Ltd. | Glycoside indoles |
WO2001074834A1 (en) | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-aryl glucoside sglt2 inhibitors and method |
WO2001074835A1 (en) | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-glucosylated benzamide sglt2 inhibitors and method |
JP2001288178A (en) | 2000-02-02 | 2001-10-16 | Kotobuki Seiyaku Kk | C-glycoside, method for producing the same and medicine containing the same |
US20020032164A1 (en) | 1998-12-30 | 2002-03-14 | Dale Roderic M. K. | Antimicrobial compounds and methods for their use |
WO2002053573A1 (en) | 2000-12-28 | 2002-07-11 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
WO2002068440A1 (en) | 2001-02-27 | 2002-09-06 | Kissei Pharmaceutical Co., Ltd. | Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
WO2002068439A1 (en) | 2001-02-26 | 2002-09-06 | Kissei Pharmaceutical Co., Ltd. | Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
WO2002070020A2 (en) | 2001-03-02 | 2002-09-12 | University Of Western Ontario | Polymer precursors of radiolabeled compounds, and methods of making and using the same |
WO2002083066A2 (en) | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
WO2002088157A1 (en) | 2001-04-27 | 2002-11-07 | Ajinomoto Co., Inc. | N-substituted pyrazolyl-o-glycoside derivatives and remedial agent for diabetes containing the same |
WO2002094262A1 (en) | 2001-05-18 | 2002-11-28 | Eli Lilly And Company | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors |
WO2003000712A1 (en) | 2001-06-20 | 2003-01-03 | Kissei Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
JP2003012686A (en) | 2001-07-02 | 2003-01-15 | Kyowa Hakko Kogyo Co Ltd | Pyrazole derivative |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US20030024914A1 (en) | 2000-12-18 | 2003-02-06 | Stephen Aleshin | Laser beam stop sensor for automatically detecting the presence of laser beam stop material |
WO2003011880A1 (en) | 2001-07-31 | 2003-02-13 | Kissei Pharmaceutical Co., Ltd. | Glucopyrano syloxybenzyl benzene derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
US6562791B1 (en) | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
WO2003043621A1 (en) | 2001-11-16 | 2003-05-30 | Cutanix Corporation | Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
US20030114390A1 (en) | 2001-03-13 | 2003-06-19 | Washburn William N. | C-aryl glucoside SGLT2 inhibitors and method |
EP1338603A1 (en) | 2000-11-02 | 2003-08-27 | Ajinomoto Co., Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
US6617313B1 (en) | 2002-03-13 | 2003-09-09 | Council Of Scientific And Industrial Research | Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof |
WO2003087104A1 (en) | 2002-04-18 | 2003-10-23 | Astrazeneca Ab | Heterocyclic compounds |
WO2004007517A1 (en) | 2002-07-11 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof |
WO2004013118A1 (en) | 2002-08-05 | 2004-02-12 | Yamanouchi Pharmaceutical Co., Ltd. | Azulene derivatives and salts thereof |
WO2004014931A1 (en) | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co., Ltd. | ARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME |
WO2004018442A1 (en) | 2002-08-23 | 2004-03-04 | Dr. Reddy's Laboratories Limited | Crystalline and amorphous forms of (s) -repaglinide and the processes for preparation thereof |
WO2004019958A1 (en) | 2002-08-27 | 2004-03-11 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof |
WO2004052903A1 (en) | 2002-12-12 | 2004-06-24 | Aventis Pharma Deutschland Gmbh | Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof |
WO2004052902A1 (en) | 2002-12-12 | 2004-06-24 | Aventis Pharma Deutschland Gmbh | Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof |
WO2004063209A2 (en) | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Methods of producing c-aryl glucoside sglt2 inhibitors |
WO2004080990A1 (en) | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | C-glycoside derivatives and salts thereof |
WO2004087727A1 (en) | 2003-03-31 | 2004-10-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
WO2004099230A1 (en) | 2003-05-12 | 2004-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
WO2004113359A1 (en) | 2003-06-20 | 2004-12-29 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, drug composition containing the same and production intermediate therefor |
US20050032711A1 (en) | 2003-08-01 | 2005-02-10 | Mona Patel | Substituted indazole-O-glucosides |
US20050032712A1 (en) | 2003-08-01 | 2005-02-10 | Maud Urbanski | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
WO2005012326A1 (en) | 2003-08-01 | 2005-02-10 | Tanabe Seiyaku Co., Ltd. | Novel compounds having inhibitory activity against sodium-dependant transporter |
US20050037980A1 (en) | 2003-08-01 | 2005-02-17 | Philip Rybczynski | Substituted fused heterocyclic C-glycosides |
US20050037981A1 (en) | 2003-08-01 | 2005-02-17 | Beavers Mary Pat | Substituted indole-O-glucosides |
WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
US20050124556A1 (en) | 2001-10-24 | 2005-06-09 | Michael Burton | Chromogenic enzyme substrates |
WO2006108842A1 (en) | 2005-04-15 | 2006-10-19 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
WO2006120208A1 (en) | 2005-05-10 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US20070060545A1 (en) | 2003-08-01 | 2007-03-15 | Tanabe Seiyaku Co., Ltd. | Novel compounds |
WO2007035198A2 (en) | 2005-07-25 | 2007-03-29 | Merck & Co., Inc. | Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
WO2007054978A2 (en) | 2005-11-10 | 2007-05-18 | Jubilant Organosys Limited | Process for preparing paroxetine hydrochloride hemihydrate |
WO2007107354A1 (en) | 2006-03-23 | 2007-09-27 | Sandoz Ag | Rosiglitazone hydrochloride hemihydrate |
US7943582B2 (en) * | 2006-12-04 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5596545B2 (en) † | 2007-09-10 | 2014-09-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Method for producing a compound useful as an inhibitor of SGLT |
-
2007
- 2007-11-20 UY UY30730A patent/UY30730A1/en not_active Application Discontinuation
- 2007-12-03 DK DK07850306.7T patent/DK2102224T4/en active
- 2007-12-03 EP EP07850306.7A patent/EP2102224B2/en active Active
- 2007-12-03 MX MX2009005857A patent/MX2009005857A/en active IP Right Grant
- 2007-12-03 CN CN2007800431547A patent/CN101573368B/en active Active
- 2007-12-03 ES ES07850306T patent/ES2456640T5/en active Active
- 2007-12-03 CN CN2012101116538A patent/CN102675380A/en active Pending
- 2007-12-03 ZA ZA200903941A patent/ZA200903941B/en unknown
- 2007-12-03 RS RS20140194A patent/RS53274B2/en unknown
- 2007-12-03 CN CN2012100910385A patent/CN102675299A/en active Pending
- 2007-12-03 BR BRPI0718882A patent/BRPI0718882B8/en active IP Right Grant
- 2007-12-03 WO PCT/JP2007/073729 patent/WO2008069327A1/en active Application Filing
- 2007-12-03 NZ NZ577545A patent/NZ577545A/en unknown
- 2007-12-03 KR KR1020097013946A patent/KR101146095B1/en active IP Right Review Request
- 2007-12-03 PL PL07850306T patent/PL2102224T5/en unknown
- 2007-12-03 ME MEP-2014-45A patent/ME01829B/en unknown
- 2007-12-03 AU AU2007329895A patent/AU2007329895C1/en active Active
- 2007-12-03 PT PT78503067T patent/PT2102224E/en unknown
- 2007-12-03 US US11/987,670 patent/US7943582B2/en active Active
- 2007-12-03 PA PA20078759401A patent/PA8759401A1/en unknown
- 2007-12-03 AR ARP070105383A patent/AR064099A1/en not_active Application Discontinuation
- 2007-12-03 JP JP2009538905A patent/JP5159788B2/en active Active
- 2007-12-03 CA CA2671357A patent/CA2671357C/en active Active
- 2007-12-03 EA EA200970540A patent/EA017103B1/en active Protection Beyond IP Right Term
- 2007-12-03 MY MYPI20092200A patent/MY153702A/en unknown
- 2007-12-03 SI SI200731417T patent/SI2102224T2/en unknown
- 2007-12-04 PE PE2013000220A patent/PE20130591A1/en active IP Right Grant
- 2007-12-04 PE PE2011001164A patent/PE20110841A1/en not_active Application Discontinuation
- 2007-12-04 TW TW096146015A patent/TWI403325B/en active
- 2007-12-04 PE PE2007001714A patent/PE20081201A1/en not_active Application Discontinuation
- 2007-12-04 CL CL200703487A patent/CL2007003487A1/en unknown
-
2009
- 2009-05-06 NO NO20091778A patent/NO344354B1/en unknown
- 2009-05-31 IL IL199032A patent/IL199032A/en active IP Right Grant
- 2009-06-04 GT GT200900151A patent/GT200900151A/en unknown
- 2009-06-04 SV SV2009003285A patent/SV2009003285A/en unknown
- 2009-06-11 CR CR10861A patent/CR10861A/en unknown
- 2009-07-02 CO CO09068422A patent/CO6210719A2/en not_active Application Discontinuation
- 2009-07-03 EC EC2009009489A patent/ECSP099489A/en unknown
-
2011
- 2011-05-09 US US13/103,557 patent/US8513202B2/en active Active
-
2017
- 2017-02-01 AR ARP170100253A patent/AR107510A2/en unknown
-
2020
- 2020-03-19 AR ARP200100781A patent/AR118450A2/en unknown
Patent Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160861A (en) | 1977-10-03 | 1979-07-10 | Merck & Co., Inc. | Method for the separation of antibiotic macrolides |
US4584369A (en) | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
JPS63233975A (en) | 1986-10-07 | 1988-09-29 | Wako Pure Chem Ind Ltd | Tcnq complex |
EP0355750A1 (en) | 1988-08-19 | 1990-02-28 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
JPH04253974A (en) | 1991-02-05 | 1992-09-09 | Ishihara Sangyo Kaisha Ltd | Sulfonylurea compound, its production and herbicide containing the same |
US5149838A (en) | 1991-09-20 | 1992-09-22 | Merck & Co., Inc. | Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents |
WO1993021178A1 (en) | 1992-04-14 | 1993-10-28 | Pfizer Limited | Indole derivatives as 5-ht1-like agonists |
EP0579204A2 (en) | 1992-07-15 | 1994-01-19 | Kao Corporation | Dye composition for a keratinous fiber |
US5424406A (en) | 1992-11-12 | 1995-06-13 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
US5731292A (en) | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
US6297363B1 (en) | 1993-02-12 | 2001-10-02 | Nomura Co., Ltd. | Glycoside indoles |
US5830873A (en) | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
WO1997025033A1 (en) | 1995-10-31 | 1997-07-17 | Eli Lilly And Company | Antithrombotic diamines |
US5767094A (en) | 1995-11-07 | 1998-06-16 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and processes for preparing the same |
JPH09263549A (en) | 1996-01-25 | 1997-10-07 | Fujisawa Pharmaceut Co Ltd | Production of benzene derivative |
US6048842A (en) | 1996-12-26 | 2000-04-11 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivatives and process for preparing the same |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
JPH10324632A (en) | 1997-03-25 | 1998-12-08 | Takeda Chem Ind Ltd | Pharmaceutical composition |
JP2000034239A (en) | 1998-07-16 | 2000-02-02 | Asahi Glass Co Ltd | Production of trifluoromethylated aromatic compound |
JP2000034230A (en) | 1998-07-17 | 2000-02-02 | Pola Chem Ind Inc | Sulfur-containing antifungal agent |
US20020032164A1 (en) | 1998-12-30 | 2002-03-14 | Dale Roderic M. K. | Antimicrobial compounds and methods for their use |
WO2000074681A1 (en) | 1999-06-03 | 2000-12-14 | Pfizer Limited | Metalloprotease inhibitors |
WO2001027128A1 (en) | 1999-10-12 | 2001-04-19 | Bristol-Myers Squibb Company | C-aryl glucoside sglt2 inhibitors |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6414126B1 (en) | 1999-10-12 | 2002-07-02 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US20010041674A1 (en) | 2000-02-02 | 2001-11-15 | Kotobujki Pharmaceutical Co., Ltd. | C-glycosides and preparation of thereof as antidiabetic agents |
JP2001288178A (en) | 2000-02-02 | 2001-10-16 | Kotobuki Seiyaku Kk | C-glycoside, method for producing the same and medicine containing the same |
US6627611B2 (en) | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
GB2359554A (en) | 2000-02-02 | 2001-08-29 | Kotobuki Pharmaceutical Compan | C-Glycosides and preparation thereof as antidiabetic agents |
WO2001064669A1 (en) | 2000-03-03 | 2001-09-07 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
US20040053855A1 (en) | 2000-03-17 | 2004-03-18 | Hideki Fujikura | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
WO2001068660A1 (en) | 2000-03-17 | 2001-09-20 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
WO2001074834A1 (en) | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-aryl glucoside sglt2 inhibitors and method |
US20020052326A1 (en) | 2000-03-30 | 2002-05-02 | Washburn William N. | O-glucosylated benzamide SGLT2 inhibitors and method |
US20020111315A1 (en) | 2000-03-30 | 2002-08-15 | Washburn William N. | O-aryl glucoside SGLT2 inhibitors and method |
WO2001074835A1 (en) | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-glucosylated benzamide sglt2 inhibitors and method |
EP1338603A1 (en) | 2000-11-02 | 2003-08-27 | Ajinomoto Co., Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
US20030024914A1 (en) | 2000-12-18 | 2003-02-06 | Stephen Aleshin | Laser beam stop sensor for automatically detecting the presence of laser beam stop material |
US20040063646A1 (en) | 2000-12-28 | 2004-04-01 | Hideki Fujikura | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
WO2002053573A1 (en) | 2000-12-28 | 2002-07-11 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
US20040132669A1 (en) | 2001-02-26 | 2004-07-08 | Toshihiro Nishimura | Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
WO2002068439A1 (en) | 2001-02-26 | 2002-09-06 | Kissei Pharmaceutical Co., Ltd. | Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
WO2002068440A1 (en) | 2001-02-27 | 2002-09-06 | Kissei Pharmaceutical Co., Ltd. | Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
US20040116357A1 (en) | 2001-02-27 | 2004-06-17 | Nobuhiko Fushimi | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
WO2002070020A2 (en) | 2001-03-02 | 2002-09-12 | University Of Western Ontario | Polymer precursors of radiolabeled compounds, and methods of making and using the same |
US20030114390A1 (en) | 2001-03-13 | 2003-06-19 | Washburn William N. | C-aryl glucoside SGLT2 inhibitors and method |
WO2002083066A2 (en) | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
US20030064935A1 (en) | 2001-04-11 | 2003-04-03 | Gougoutas Jack Z. | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
WO2002088157A1 (en) | 2001-04-27 | 2002-11-07 | Ajinomoto Co., Inc. | N-substituted pyrazolyl-o-glycoside derivatives and remedial agent for diabetes containing the same |
US20040110936A1 (en) | 2001-04-27 | 2004-06-10 | Ajinomoto Co., Inc. | N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same |
WO2002094262A1 (en) | 2001-05-18 | 2002-11-28 | Eli Lilly And Company | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors |
WO2003000712A1 (en) | 2001-06-20 | 2003-01-03 | Kissei Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
JP2003012686A (en) | 2001-07-02 | 2003-01-15 | Kyowa Hakko Kogyo Co Ltd | Pyrazole derivative |
WO2003011880A1 (en) | 2001-07-31 | 2003-02-13 | Kissei Pharmaceutical Co., Ltd. | Glucopyrano syloxybenzyl benzene derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
US20030087843A1 (en) | 2001-09-05 | 2003-05-08 | Washburn William N. | O-pyrazole glucoside SGLT2 inhibitors and method of use |
WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
US20050124556A1 (en) | 2001-10-24 | 2005-06-09 | Michael Burton | Chromogenic enzyme substrates |
WO2003043621A1 (en) | 2001-11-16 | 2003-05-30 | Cutanix Corporation | Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
US6617313B1 (en) | 2002-03-13 | 2003-09-09 | Council Of Scientific And Industrial Research | Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof |
US6562791B1 (en) | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
WO2003087104A1 (en) | 2002-04-18 | 2003-10-23 | Astrazeneca Ab | Heterocyclic compounds |
WO2003099836A1 (en) | 2002-05-20 | 2003-12-04 | Bristol-Myers Squibb Company | C-aryl glucoside sglt2 inhibitors and method |
WO2004007517A1 (en) | 2002-07-11 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof |
US20040138143A1 (en) | 2002-07-11 | 2004-07-15 | Heiner Glombik | Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof |
WO2004013118A1 (en) | 2002-08-05 | 2004-02-12 | Yamanouchi Pharmaceutical Co., Ltd. | Azulene derivatives and salts thereof |
CA2494177A1 (en) | 2002-08-05 | 2004-02-12 | Yamanouchi Pharmaceutical Co., Ltd. | Azulene derivatives and salts thereof for use as na+-glucose cotransporter inhibitors |
WO2004014931A1 (en) | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co., Ltd. | ARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME |
EP1528066A1 (en) | 2002-08-09 | 2005-05-04 | Taisho Pharmaceutical Co., Ltd | Aryl 5-thio-d-glucopyranoside derivatives and remedies for diabetes containing the same |
WO2004018442A1 (en) | 2002-08-23 | 2004-03-04 | Dr. Reddy's Laboratories Limited | Crystalline and amorphous forms of (s) -repaglinide and the processes for preparation thereof |
WO2004019958A1 (en) | 2002-08-27 | 2004-03-11 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof |
WO2004052902A1 (en) | 2002-12-12 | 2004-06-24 | Aventis Pharma Deutschland Gmbh | Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof |
WO2004052903A1 (en) | 2002-12-12 | 2004-06-24 | Aventis Pharma Deutschland Gmbh | Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof |
US20050014704A1 (en) | 2002-12-12 | 2005-01-20 | Aventis Pharma Deutschland Gmbh | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof |
US20040259819A1 (en) | 2002-12-12 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof |
WO2004063209A2 (en) | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Methods of producing c-aryl glucoside sglt2 inhibitors |
US7375213B2 (en) | 2003-01-03 | 2008-05-20 | Bristol-Myers Squibb Company | Methods of producing C-aryl glucoside SGLT2 inhibitors |
WO2004080990A1 (en) | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | C-glycoside derivatives and salts thereof |
WO2004087727A1 (en) | 2003-03-31 | 2004-10-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
WO2004099230A1 (en) | 2003-05-12 | 2004-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
WO2004113359A1 (en) | 2003-06-20 | 2004-12-29 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, drug composition containing the same and production intermediate therefor |
US20050032712A1 (en) | 2003-08-01 | 2005-02-10 | Maud Urbanski | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
US20050032711A1 (en) | 2003-08-01 | 2005-02-10 | Mona Patel | Substituted indazole-O-glucosides |
US20050037980A1 (en) | 2003-08-01 | 2005-02-17 | Philip Rybczynski | Substituted fused heterocyclic C-glycosides |
WO2005012326A1 (en) | 2003-08-01 | 2005-02-10 | Tanabe Seiyaku Co., Ltd. | Novel compounds having inhibitory activity against sodium-dependant transporter |
US20050233988A1 (en) | 2003-08-01 | 2005-10-20 | Tanabe Seiyaku Co., Ltd. | Novel compounds |
US20060217323A1 (en) | 2003-08-01 | 2006-09-28 | Mona Patel | Substituted indazole-O-glucosides |
US20060229260A1 (en) | 2003-08-01 | 2006-10-12 | Philip Rybczynski | Substituted fused heterocyclic C-glycosides |
US20060234954A1 (en) | 2003-08-01 | 2006-10-19 | Maud Urbanski | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
US20050037981A1 (en) | 2003-08-01 | 2005-02-17 | Beavers Mary Pat | Substituted indole-O-glucosides |
US7511022B2 (en) | 2003-08-01 | 2009-03-31 | Janssen Pharmaceutica N.V. | Substituted indole-O-glucosides |
US20060293251A1 (en) | 2003-08-01 | 2006-12-28 | Maud Urbanski | Substituted indazole-O-glucosides |
US20070060545A1 (en) | 2003-08-01 | 2007-03-15 | Tanabe Seiyaku Co., Ltd. | Novel compounds |
WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2006108842A1 (en) | 2005-04-15 | 2006-10-19 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
WO2006120208A1 (en) | 2005-05-10 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
WO2007035198A2 (en) | 2005-07-25 | 2007-03-29 | Merck & Co., Inc. | Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
WO2007054978A2 (en) | 2005-11-10 | 2007-05-18 | Jubilant Organosys Limited | Process for preparing paroxetine hydrochloride hemihydrate |
WO2007107354A1 (en) | 2006-03-23 | 2007-09-27 | Sandoz Ag | Rosiglitazone hydrochloride hemihydrate |
US7943582B2 (en) * | 2006-12-04 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Non-Patent Citations (136)
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11576894B2 (en) | 2009-07-08 | 2023-02-14 | Janssen Pharmaceutica Nv | Combination therapy for the treatment of diabetes |
US10617668B2 (en) | 2010-05-11 | 2020-04-14 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
US10544135B2 (en) | 2011-04-13 | 2020-01-28 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US9573959B2 (en) | 2013-03-14 | 2017-02-21 | Msd International Gmbh | Methods for preparing SGLT2 inhibitors |
WO2014195966A2 (en) | 2013-05-30 | 2014-12-11 | Cadila Healthcare Limited | Amorphous form of canagliflozin and process for preparing thereof |
WO2021214023A1 (en) | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2022067724A1 (en) | 2020-09-30 | 2022-04-07 | 北京睿创康泰医药研究院有限公司 | Sglt-2 inhibitor sarcosine co-crystal, preparation method therefor and use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8513202B2 (en) | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | |
KR101249711B1 (en) | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | |
TWI482778B (en) | Method for the preparation of a crystalline form | |
RU2476438C2 (en) | Solid forms of macrolides | |
KR20080053369A (en) | CRYSTALLINE FORMS OF 1-CHLORO-4-(Beta;-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | |
PH12012500168B1 (en) | Crystalline solvates and complexes of (is)-1,5-anhydro-l-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes | |
US20090298947A1 (en) | Polymorphic and amorphous forms of lacosamide and amorphous compositions | |
TW200927105A (en) | Process for the preparation of compounds useful as inhibitors of SGLT | |
CA2773713A1 (en) | Novel trpa1 antagonists | |
TW201837033A (en) | Salt of [mu]-opioid receptor (MOR) agonist, fumarate I crystal form thereof and preparation method thereof | |
WO2017206827A1 (en) | Crystal form of sodium-glucose cotransporter 2 inhibitor | |
EP2155698A1 (en) | Novel thermodynamically stable polymorphic form-l of letrozole | |
KR101322116B1 (en) | Novel crystal of substituted phenylalkanoic acid and production process | |
EP1674468A1 (en) | Polymorphs of clopidogrel hydrobromide | |
WO2021121270A1 (en) | Method for purifying sglts inhibitor and application thereof | |
KR20240025619A (en) | Crystalline potassium salt of 1-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide | |
WO2000051959A1 (en) | Fluorinated chalcone derivatives or salts thereof and drugs containing the same as the active ingredient | |
KR20200003645A (en) | Novel crystal form(s) and method of preparing thereof | |
CA2614048A1 (en) | Improved crystalline form of the compound a-348441 | |
JP2002161100A (en) | 4-alkoxy-2,3,6-trimethylphenylmannoside and medicine containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JAPAN Free format text: CHANGE OF ADDRESS;ASSIGNOR:MITSUBISHI TANABE PHARMA CORPORATION;REEL/FRAME:037163/0890 Effective date: 20150401 |
|
AS | Assignment |
Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JAPAN Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 037163 FRAME 0890. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ADDRESS IS AS FOLLOWS:3-2-10, DOSHO-MACHI, CHUO-KU, OSAKA-SHI, OSAKA, 541-8505 JAPAN;ASSIGNOR:MITSUBISHI TANABE PHARMA CORPORATION;REEL/FRAME:037354/0934 Effective date: 20150401 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |